Skip to main content

Table 2 Univariate analysis of pMT1-MMP expression in clinicopathologic features

From: Identification of membrane-type 1 matrix metalloproteinase tyrosine phosphorylation in association with neuroblastoma progression

Characteristics N* Mean intensity Positive
N (%)
Negative
N (%)
P
Type of samples      
   Normal control samples 56 0.34 19 (33.9) 37 (66.1)  
   Tumor from primary site 289 0.72 187 (64.7) 102 (35.3) 0.0001
   Tumor from metastasis 103 0.72 76 (73.8) 27 (26.2) 0.5900
Age      
   < 1 year 125 0.64 58 (46.4) 67 (53.6) 0.0002
   > 1 year 184 0.78 124 (67.4) 60 (32.6)  
Clinical stage      
   1 68 0.66 41 (60.3) 27 (39.7) 0.3700
   4 103 0.75 69 (67.0) 34 (33.0)  
Specimen type      
   Mass screening 55 0.31 24 (43.6) 31 (56.4) 0.0006
   Standard 234 0.8 160 (68.4) 74 (31.6)  
MYCN oncogene      
   Amplified 34 0.52 21 (61.8) 13 (38.2) 0.1000
   Not amplified 214 0.69 100 (46.7) 114 (53.3)  
  1. *N: number of specimens